Archer’s A1 Biochip Development Commences
November 6, 2020 | Archer Materials LimitedEstimated reading time: 3 minutes
Archer Materials Limited is pleased to announce the Company has commenced building a lab-on-a-chip device (“biochip”) named A1 Biochip™.
Archer has made a step-change in advancing its graphene-based biosensor technology development to newly commence its lab-on-a-chip A1 Biochip™ project. This was possible in a short period of time as Archer brought its biotechnology development in-house and is now able to miniaturise its biosensing processes to chip-formats while retaining its IP.
Archer will be designing and building its own biochip which means that the Company no longer requires prototyping sensor materials, graphene inks, 2D/3D printing, or circuit boards (manufactured in Asia) (ASX Ann. 31 Aug 2020). Developing the biochip in-house should allow Archer to accelerate commercialisation of the biochip.
Commenting on the A1 Biochip™ development, Archer CEO Dr Mohammad Choucair said: “It is a global challenge to develop innovative biodevices that make the complex detection of disease safer and more reliable. Archer’s A1 Biochip™ technology aims to simplify disease detection at the point of care to potentially address an emerging multibillion dollar industry. “Archer’s biochip development involves miniaturising medical lab tests onto an integrated circuit, a single chip, that is only a few millimetres in size. This is incredibly difficult, and there are very few people the world that can do this type of work, however Dr Soffe has already made exciting advances on this front in only a few weeks since joining Archer."
Archer’s A1 Biochip™
Key features include the onchip microfluidic channels that allow for gas or liquid sampling (typical biological specimens) and the miniaturised electrodes for the biosensing areas (microfabricated using gold and titanium).
Biochip development will involve designing these components for further miniaturisation (micron to nanoscale), and are intended to incorporate graphene materials; both aspects which are required to validate commercial advantages of ultra-sensitivity and device integration.
Miniaturising and integrating a lab-on-chip device also provides improved accuracy and a substantial decrease in the time required to obtain a diagnostic test result, which are key commercial barriers to point of care medical diagnostic disease testing. Specifically:
- Archer’s biochip componentry and design solves for sample evaporation challenges and substantially overcome limitations in fabricating the active sensing areas to meet miniaturisation requirements for viable disease detection.
- The biochip microfluidics allow sample sorting, preparation, and handling – all on-chip. Sample volumes as small as 3 microlitres (“µL”) can be used – comparable to the volume of a tear drop (6-7 µL) or blood droplet (50 µL) – which is more than 1000 times less than the volume taken for a regular blood test (3-10 mL).
Archer streamlining its go-to-market strategy
A new commercial agreement now allows Archer to access the world-class semiconductor chip prototyping foundry (“Foundry”) for all its technology development. The Company’s biochip development is led by Dr Rebecca Soffe (ASX Ann. 10 Sept 2020) (Image 2). Archer has begun building its biochip in the Foundry alongside its 12CQ quantum computing chip development.
Archer has worked with its German Biotech partner to 3D print human antibodies (e.g. Human IgG) (ASX Ann. 15 Apr 2019) which are relevant biomolecules in the immune system response caused by certain diseases, including respiratory diseases like COVID-19. The Company intends to translate this knowledge to its biochip development, and will continue exploring potential onchip conversion of current diagnostics with the German Biotech teams.
Archer will work with its German Biotech partner to determine potential candidate biomolecules relevant to in-demand disease diagnostic tests, as part of the commercial development of Archer’s A1 Biochip™. The immediate next technology validation steps will be performed in the Foundry, and focus on translating the biochip components onto silicon wafers. This is important as it would enable the possibility of high volume chip production and integration onboard electronic devices – both required for any future retail applications of the A1 Biochip™.
A materials technology company developing innovative deep tech in quantum computing, biotechnology, and reliable energy. The Company has strong intellectual property, world-class in-house expertise, a unique materials inventory, and access to Tier 1 technology development infrastructure.
Suggested Items
Warm Windows and Streamlined Skin Patches – IDTechEx Explores Flexible and Printed Electronics
04/26/2024 | IDTechExFlexible and printed electronics can be integrated into cars and homes to create modern aesthetics that are beneficial and easy to use. From luminous car controls to food labels that communicate the quality of food, the uses of this technology are endless and can upgrade many areas of everyday life.
iNEMI Packaging Tech Topic Series: Role of EDA in Advanced Semiconductor Packaging
04/26/2024 | iNEMIAdvanced semiconductor packaging with heterogenous integration has made on-package integration of multiple chips a crucial part of finding alternatives to transistor scaling. Historically, EDA tools for front-end and back-end design have evolved separately; however, design complexity and the increased number of die-to-die or die-to-substrate interconnections has led to the need for EDA tools that can support integration of overall design planning, implementation, and system analysis in a single cockpit.
Koh Young Showcases Award-winning Inspection Solutions at SMTconnect with SmartRep in Hall 4A.225
04/25/2024 | Koh Young TechnologyKoh Young Technology, the industry leader in True 3D measurement-based inspection solutions, will showcase an array of award-winning inspection and measurement solutions at SMTconnect alongside its sales partner, SmartRep, in booth 4A.225 at NürnbergMesse from June 11-13, 2023. The following offers a glimpse into what Koh Young will present at the tradeshow:
Real Time with… IPC APEX EXPO 2024: Plasmatreat: Innovative Surface Preparation Solutions
04/25/2024 | Real Time with...IPC APEX EXPOIn this interview, Editor Nolan Johnson speaks with Hardev Grewal, CEO and president of Plasmatreat, a developer of atmospheric plasma solutions. Plasmatreat uses clean compressed air and electricity to create plasma, offering environmentally friendly methods for surface preparation. Their technology measures plasma density for process optimization and can remove organic micro-contamination. Nolan and Hardev also discuss REDOX-Tool, a new technology for removing metal oxides.
Nanotechnology Market to Surpass $53.51 Billion by 2031
04/25/2024 | PRNewswireSkyQuest projects that the nanotechnology market will attain a value of USD 53.51 billion by 2031, with a CAGR of 36.4% over the forecast period (2024-2031).